Oncology & Cancer

Why some brain tumors respond to immunotherapy

Columbia researchers have learned why some glioblastomas—the most common type of brain cancer—respond to immunotherapy. The findings could help identify patients who are most likely to benefit from treatment with immunotherapy ...

Oncology & Cancer

Immune stimulant molecule shown to prevent cancer

A research team at the University of Louisville has discovered that an immune checkpoint molecule they developed for cancer immunotherapy, also protects against future development of multiple types of cancer when administered ...

Oncology & Cancer

Nullifying protein YTHDF1 enhances anti-tumor response

Cancer immunotherapy—an approach that removes the barriers that protect cancer cells from a patient's immune system—has revolutionized the treatment of many cancer types. About 40 percent of melanoma patients, for example, ...

Oncology & Cancer

Regulation and potential drug targets of tumor-associated Tregs

According to estimates from the World Health Organization (WHO), there will be 18.1 million new cases and 9.6 million cancer deaths worldwide in 2018. Cancer is a serious disease that affects people all over the world. And ...

Oncology & Cancer

Scientists advise caution in immunotherapy research

In a new study, Yale Cancer Center (YCC) scientists suggest that as the number of clinical trials in cancer immunotherapy grows exponentially, some caution should be exercised as we continue to better understand the biology ...

page 34 from 40